2 stories
A Peterson-KFF Health System Tracker analysis compared prices for 32 brand-name drugs on TrumpRx.gov—a federal portal launched in February 2026 offering medications from manufacturers that signed voluntary pricing agreements with the White House—to publicly listed prices in 11 wealthy OECD countries. TrumpRx prices were lower than the OECD peer average for 17 drugs and higher for 15; TrumpRx had the lowest price for 5 drugs and the highest for 13. The analysis does not assess whether these negotiated prices affect Medicaid or Medicare reimbursement, whether domestic prices outside TrumpRx have changed, or how the retail prices compare to net costs after rebates in Medicaid or other public programs.
Health insurers have submitted 2027 rate filings to state regulators for individual market plans sold through ACA Marketplaces, showing premium increases. The filings detail insurer expectations and the factors driving rate changes for the coming plan year. Rate filings occur annually each spring and summer as part of the regulatory approval process. This development affects individual market plans, which operate separately from Medicaid managed care but may inform broader health plan pricing trends and cost drivers affecting the commercial insurance market.
Get the daily briefing.